You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

674 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Document
Mar 2021
Document
Mar 2021
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969

Pages